CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
It affects up to 10 per cent of women of reproductive age around the world
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Tembo and UFlex-Asepto have co-developed 100% renewable and recyclable paper straw solution that will be food grade, moisture-resistant and made from sustainably sourced papers
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
He has extensive leadership experience across supply chain and has worked at companies such as Unilever, Flipkart, Colgate-Palmolive & Mondelez
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
Subscribe To Our Newsletter & Stay Updated
